Europe Continues To Drag On Reckitt Despite Boost From SSL
This article was originally published in The Tan Sheet
Executive Summary
European sales continue to drag on Reckitt Benckiser even as newly acquired SSL brands contribute heavily to growth, the firm reports July 25.
You may also be interested in...
Reckitt Reorganizes To Develop Health Care, Emerging Markets
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.
Reckitt Reorganizes To Develop Health Care, Emerging Markets
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.
In Brief
Watson prevails in Mucinex patent ruling